Partner with us

At the Neuroscience Institute we understand the vital link between research and industry application.

Brain scans

We are proud to work in collaboration with a number of charities, global institutes and leading global organisations and seek new and exciting opportunities to further enhance our translational research.

By working together we believe we can find novel solutions to the biggest neurological challenges and help to change lives.

The Neuroscience Institute
University of Sheffield
385a Glossop Road
Sheffield
South Yorkshire
S10 2HQ
neuroscience@sheffield.ac.uk


Collaborations with business and industry

Discover how our pioneering partnerships are accelerating discoveries and understanding.

Medical research pharmaceutical factory laboratory

Keapstone Therapeutics

The University of Sheffield and Parkinson’s UK have launched a new £1 million virtual biotech company as part of a pioneering research programme to create new drugs for Parkinson’s Disease.

In a partnership which is the first of its kind, Keapstone Therapeutics combines world-leading research with funding and expertise from the charity to help develop revolutionary drug for Parkinson’s, which affects around 127,000 people in UK.

World-first partnership to develop new drugs for Parkinson’s

Neurons

Resagen: Therapy for damaged motor neurons

Professor Mimoun Azzouz, Chair of Translational Neuroscience, has been investigating a gene therapy for spinal muscular atrophy (SMA), a rare neurodegenerative disease affecting babies and children caused by mutations to a single gene, for more than a decade.

His extensive research data has provided promising proof of concept for Resagen, a potential gene therapy product for patients with SMA. Applying this research could lead to a safe and effective treatment, ongoing work continues with the hope of starting clinical trials in the near future.

Towards a safe and effective treatment

Neurotransmitters

FORMA Therapeutics

Researchers from the University of Sheffield secured a partnership with a US-based biotechnology company to help progress their pioneering translational research.

The new collaboration with FORMA Therapeutics focuses on using patient cells to understand the complex biology underpinning Parkinson’s and Amyotrophic Lateral Sclerosis (ALS) and to harness this technology for novel drug discovery.

Accelerating treatments for Parkinson's